Jingqin Rosy Luo

This study identifies senescent cancer-associated fibroblasts (senCAFs) driven by MK2 that promote immunosuppression in bone metastases and shows that combining MK2 inhibition with OX40 agonists enhances immunotherapy efficacy.

This study shows that platelet PAR4 signaling, interacting with estrogen receptor beta, drives glioblastoma progression and immune suppression, with sex-specific effects on survival and TME dynamics.

This study identifies EGR1 as a key driver of sex differences in glioblastoma tumorigenicity, showing it mediates survival and treatment response differences between males and females.

This study shows that daily glucocorticoids influence glioblastoma growth and circadian synchronization with the host, with effects dependent on timing and clock genes.

This study quantifies kinase protein abundance in human tissues using proteomic mass spectrometry, revealing heterogeneity in breast cancer subtypes and enabling clinical applications.

The paper identifies somatic mutations with prognostic effects in ER+ breast cancer using genomic data from multiple cohorts.